Cargando…

Molecular imaging to support cancer immunotherapy

The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in improved survival of patients across several tumor types. However, not all pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	van de Donk, Pim P, Oosting, Sjoukje F, Knapen, Daan G, van der Wekken, Anthonie J, Brouwers, Adrienne H, Lub-de Hooge, Marjolijn N, de Groot, Derk-Jan A, de Vries, Elisabeth GE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352987/ https://www.ncbi.nlm.nih.gov/pubmed/35922089 http://dx.doi.org/10.1136/jitc-2022-004949

Ejemplares similares

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
por: van Sluis, Joyce, et al.
Publicado: (2022)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

Whole-body CD8(+) T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
por: Kist de Ruijter, Laura, et al.
Publicado: (2022)

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
por: Pool, Martin, et al.
Publicado: (2017)

Pharmacokinetic Boosting of Kinase Inhibitors
por: Westra, Niels, et al.
Publicado: (2023)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer (89)Zr-imgatuzumab
por: Pool, Martin, et al.
Publicado: (2016)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017)

Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice
por: Waaijer, Stijn J. H., et al.
Publicado: (2021)

(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
por: Bensch, Frederike, et al.
Publicado: (2018)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
por: Giesen, Danique, et al.
Publicado: (2022)

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape
por: Oosting, Sjoukje F, et al.
Publicado: (2017)

The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review
por: Wiersma, Thomas K., et al.
Publicado: (2022)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
por: ter Weele, Eva J., et al.
Publicado: (2015)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Clinical-grade N-(4-[(18)F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans
por: van der Veen, Elly L., et al.
Publicado: (2019)

VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
por: Arjaans, Marlous, et al.
Publicado: (2016)

Modelling Tools to Characterize Acetaminophen Pharmacokinetics in the Pregnant Population
por: Brookhuis, Sofie A. M., et al.
Publicado: (2021)

Optimisation of scan duration and image quality in oncological (89)Zr immunoPET imaging using the Biograph Vision PET/CT
por: van Sluis, Joyce, et al.
Publicado: (2023)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

PET/CT Imaging of (89)Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys
por: Li, Wenping, et al.
Publicado: (2020)

Perspectives on imaging and immunotherapy: a review series
por: de Vries, Elisabeth GE, et al.
Publicado: (2022)

Molecular imaging: what can be used today: Monday 3 October 2005, 11:15–12:00
por: Jager, P L, et al.
Publicado: (2005)

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
por: Cichocki, Frank, et al.
Publicado: (2023)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types
por: Lamberts, Laetitia E., et al.
Publicado: (2015)

Pancreatic cyst development: insights from von Hippel-Lindau disease
por: van Asselt, Sophie J, et al.
Publicado: (2013)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
por: Oosting, Sjoukje F., et al.
Publicado: (2019)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma
por: Kruizinga, Roeliene C., et al.
Publicado: (2016)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers
por: Peters, Marloes A. M., et al.
Publicado: (2019)

Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
por: van de Donk, Pim P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_im3pvf415ek7avugjejv8bnqhb